Dmitriy Y. Kanner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dmitriy Y. Kanner has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- A. O. Shveykin
Moscow City Oncology Hospital No. 62
6 shared publications - Andrei B. Ryabov
Hertzen Moscow Oncology Research Institute
2 shared publications - M.V. Moskalets
Moscow City Oncological Hospital No. 62
2 shared publications - N. M. Abdulkhakkimov
Hertzen Moscow Oncology Research Institute
2 shared publications - S. A. Sokolov
Moscow City Oncology Hospital No. 62
2 shared publications - Sergey S. Pirogov
P.A. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia
2 shared publications
Latest Publications
- 10 August 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (4)
Endoluminal endoscopic surgery in the treatment of patients with early cardioesophageal junction cancer: a comparative analysis with surgical treatment
Objective. To compare the immediate outcomes, long-term oncological outcomes, and quality of life after endoscopic submucosal dissection and surgery in patients with early cardioesophageal cancer (cTis–cT1N0M0, Siewert type II), and to evaluate the possibility of expanding indications for dissection in comorbid patients. Material and methods. A non-randomized multicenter study included 98 patients (endoscopic treatment — 74, surgery — 24). Due to the low radicality of mucosal resection, only the endoscopic submucosal dissection subgroup (n=55) was compared with surgery. After pseudorandomization, two groups of 24 patients each were formed. We analyzed 5-year overall survival, local control, progression-free survival, complications, hospital stay, and quality of life. Results. Endoscopic submucosal dissection compared with surgery (after pseudorandomization, n=24 each): overall survival 87.5% and 90.5% (p=0.7); local control 95.8% and 94.4% (p=0.98); progression-free survival 95.8% and 90.5% (p=0.58); hospital stay 7 and 11 days (p=0.0002); quality of life (total score of the questionnaire, higher — worse) 0.9 and 7 points (p=0.00002). After surgery, quality of life deteriorated (p=0.02), whereas after dissection it did not change (p=0.371). In 13 comorbid patients (Charlson 7—8, ASA III), dissection was performed according to indications expanded relative to standard criteria (comparison with the standard indication group, n=40): tumor size 20 vs 15 mm, p=0.03; cT1b invasion 92.3% vs 17.5%, p=0.00026; poorly differentiated adenocarcinoma 30.8% vs 5%, p=0.016, respectively. Five-year results (expanded indications vs standard): local control 92.3% vs 97.3% (p=0.36), overall survival 59.1% vs 81.2% (p=0.62), progression-free survival 79.4% vs 97.3% (p=0.008), respectively. Conclusion. Endoscopic submucosal dissection for early cardioesophageal junction cancer is non-inferior to surgery in terms of overall survival, local control, and progression-free survival, while providing a shorter hospital stay and better quality of life. Expanding indications is possible in comorbid patients but requires strict dynamic monitoring.
- 10 August 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (4)
Endoluminal endoscopic surgery in the treatment of patients with early cardioesophageal junction cancer: a comparative analysis with surgical treatment
Objective. To compare the immediate outcomes, long-term oncological outcomes, and quality of life after endoscopic submucosal dissection and surgery in patients with early cardioesophageal cancer (cTis–cT1N0M0, Siewert type II), and to evaluate the possibility of expanding indications for dissection in comorbid patients. Material and methods. A non-randomized multicenter study included 98 patients (endoscopic treatment — 74, surgery — 24). Due to the low radicality of mucosal resection, only the endoscopic submucosal dissection subgroup (n=55) was compared with surgery. After pseudorandomization, two groups of 24 patients each were formed. We analyzed 5-year overall survival, local control, progression-free survival, complications, hospital stay, and quality of life. Results. Endoscopic submucosal dissection compared with surgery (after pseudorandomization, n=24 each): overall survival 87.5% and 90.5% (p=0.7); local control 95.8% and 94.4% (p=0.98); progression-free survival 95.8% and 90.5% (p=0.58); hospital stay 7 and 11 days (p=0.0002); quality of life (total score of the questionnaire, higher — worse) 0.9 and 7 points (p=0.00002). After surgery, quality of life deteriorated (p=0.02), whereas after dissection it did not change (p=0.371). In 13 comorbid patients (Charlson 7—8, ASA III), dissection was performed according to indications expanded relative to standard criteria (comparison with the standard indication group, n=40): tumor size 20 vs 15 mm, p=0.03; cT1b invasion 92.3% vs 17.5%, p=0.00026; poorly differentiated adenocarcinoma 30.8% vs 5%, p=0.016, respectively. Five-year results (expanded indications vs standard): local control 92.3% vs 97.3% (p=0.36), overall survival 59.1% vs 81.2% (p=0.62), progression-free survival 79.4% vs 97.3% (p=0.008), respectively. Conclusion. Endoscopic submucosal dissection for early cardioesophageal junction cancer is non-inferior to surgery in terms of overall survival, local control, and progression-free survival, while providing a shorter hospital stay and better quality of life. Expanding indications is possible in comorbid patients but requires strict dynamic monitoring.
- 10 August 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (4) , 88-90
Metastasis of colorectal cancer to the adrenal glands
This article presents a clinical case of a patient with colorectal cancer and atypical metastatic adrenal involvement who underwent comprehensive treatment at Moscow City Oncology Hospital No. 62. This case illustrates the importance of an individualized approach to treatment of adrenal metastases. Despite the extranodal location, combined treatment achieved disease control, highlighting the potential of integrating surgery and systemic therapy in limited metastatic disease.
- 10 August 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (4) , 88-90
Metastasis of colorectal cancer to the adrenal glands
This article presents a clinical case of a patient with colorectal cancer and atypical metastatic adrenal involvement who underwent comprehensive treatment at Moscow City Oncology Hospital No. 62. This case illustrates the importance of an individualized approach to treatment of adrenal metastases. Despite the extranodal location, combined treatment achieved disease control, highlighting the potential of integrating surgery and systemic therapy in limited metastatic disease.
- Open Access
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 127-136
Personalized organ-preserving approach to the treatment of early esophagogastric junction cancer: a case repor
Background. Early esophagogastric junction cancer with submucosal invasion (pT1b) has traditionally been an indication for radical esophagectomy due to the risk of lymphatic metastasis. However, accumulating evidence points to heterogeneity in the biological behavior of these tumors: in patients with a favorable histological profile (low-grade differentiation, absence of lymphovascular and perineural invasion), the rate of metastasis may be comparable to postoperative mortality associated with esophagectomy. A personalized organ‑preserving approach including endoscopic submucosal dissection (ESD) and intraoperative indocyanine green (ICG) navigation of sentinel lymph nodes may potentially avoid debilitating surgery in selected patients. Nevertheless, the safety and efficacy of this strategy for deep submucosal invasion (sm2, depth >500 μm) remain controversial. Case presentation. A 63‑year‑old patient with early esophagogastric junction cancer (cT1aN0M0, Siewert type II ) underwent combined modality treatment including laparoscopic ICG navigation with removal of two sentinel lymph nodes along the lesser curvature of the stomach (frozen‑section analysis showed no metastases) and simultaneous endoscopic submucosal dissection (ESD). Final histopathological examination of the resected specimen revealed a well‑differentiated adenocarcinoma pT1b sm2 (>500 μm) with no lymphovascular or perineural invasion, a negative vertical margin, but scattered tumor cells in the coagulated horizontal margin. Two months later, residual tumor was diagnosed and repeat ESD achieved R0 resection. Seventeen months after the primary procedure, a solitary lymphogenous metastasis was detected along the left gastric artery. Laparoscopic selective lymphadenectomy and adjuvant polychemotherapy (8 cycles of XELOX) were performed. No signs of recurrence were observed 4.5 years after repeat ESD and 3 years after lymphadenectomy. Conclusion. This case report demonstrates that a personalized organ‑preserving approach (ESD with ICG‑guided sentinel lymph node navigation) can be implemented in carefully selected patients with early high‑risk esophagogastric junction cancer (pT1b sm2) and favorable histological characteristics (G1–2, L0, V0). Strict multimodal surveillance enables timely detection of oligometastatic progression and selective lymphadenectomy, thereby avoiding esophagectomy and preserving quality of life. Further data accumulation is needed to refine patient selection criteria and optimize follow‑up protocols.
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 127-136
Open AccessPersonalized organ-preserving approach to the treatment of early esophagogastric junction cancer: a case repor
Background. Early esophagogastric junction cancer with submucosal invasion (pT1b) has traditionally been an indication for radical esophagectomy due to the risk of lymphatic metastasis. However, accumulating evidence points to heterogeneity in the biological behavior of these tumors: in patients with a favorable histological profile (low-grade differentiation, absence of lymphovascular and perineural invasion), the rate of metastasis may be comparable to postoperative mortality associated with esophagectomy. A personalized organ‑preserving approach including endoscopic submucosal dissection (ESD) and intraoperative indocyanine green (ICG) navigation of sentinel lymph nodes may potentially avoid debilitating surgery in selected patients. Nevertheless, the safety and efficacy of this strategy for deep submucosal invasion (sm2, depth >500 μm) remain controversial. Case presentation. A 63‑year‑old patient with early esophagogastric junction cancer (cT1aN0M0, Siewert type II ) underwent combined modality treatment including laparoscopic ICG navigation with removal of two sentinel lymph nodes along the lesser curvature of the stomach (frozen‑section analysis showed no metastases) and simultaneous endoscopic submucosal dissection (ESD). Final histopathological examination of the resected specimen revealed a well‑differentiated adenocarcinoma pT1b sm2 (>500 μm) with no lymphovascular or perineural invasion, a negative vertical margin, but scattered tumor cells in the coagulated horizontal margin. Two months later, residual tumor was diagnosed and repeat ESD achieved R0 resection. Seventeen months after the primary procedure, a solitary lymphogenous metastasis was detected along the left gastric artery. Laparoscopic selective lymphadenectomy and adjuvant polychemotherapy (8 cycles of XELOX) were performed. No signs of recurrence were observed 4.5 years after repeat ESD and 3 years after lymphadenectomy. Conclusion. This case report demonstrates that a personalized organ‑preserving approach (ESD with ICG‑guided sentinel lymph node navigation) can be implemented in carefully selected patients with early high‑risk esophagogastric junction cancer (pT1b sm2) and favorable histological characteristics (G1–2, L0, V0). Strict multimodal surveillance enables timely detection of oligometastatic progression and selective lymphadenectomy, thereby avoiding esophagectomy and preserving quality of life. Further data accumulation is needed to refine patient selection criteria and optimize follow‑up protocols.
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 6-9
First experience of robotic minimally invasive esophagectomy for esophageal cancer. Retrospective study
Background. Over the past 10 to 15 years, robot-assisted esophageal resections have transitioned from an experimental technique to a significant component of surgical management for esophageal cancer. International experience has demonstrated that this approach achieves oncological outcomes comparable to those of open and conventional minimally invasive procedures, while also reducing postoperative complications. Aim. To evaluate the outcomes of surgical treatment for esophageal cancer using robot-assisted minimally invasive resections. Materials and methods. A retrospective analysis was conducted on 13 patients with intrathoracic esophageal cancer who underwent surgery between 2024 and 2025. All patients received Lewis and McKeown robot-assisted minimally invasive esophageal resections. The DaVinci Xi robotic platform was utilized during the thoracic stage in all cases. At the abdominal stage, both robotic and standard laparoscopic approaches were employed, with one patient requiring a laparotomy. Results. The mean duration of surgery was 424.2 ± 132.2 minutes (95% confidence interval: 344.2–504.1). Median intraoperative blood loss was 96.2 mL (interquartile range: 50–100). The median intensive care unit stay following surgery was 3 days (interquartile range: 1–2.5). Postoperatively, pneumonia was the most frequent complication, occurring in three patients (23%). The most severe complication was esophagogastric anastomosis dehiscence, observed in two patients (15%). In one case (7.7%), esophagogastric anastomosis dehiscence following Lewis surgery resulted in death. Conclusion. Robot-assisted resection for esophageal cancer represents an advanced and promising surgical approach that integrates oncological radicality with enhanced safety.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 6-9
Open AccessFirst experience of robotic minimally invasive esophagectomy for esophageal cancer. Retrospective study
Background. Over the past 10 to 15 years, robot-assisted esophageal resections have transitioned from an experimental technique to a significant component of surgical management for esophageal cancer. International experience has demonstrated that this approach achieves oncological outcomes comparable to those of open and conventional minimally invasive procedures, while also reducing postoperative complications. Aim. To evaluate the outcomes of surgical treatment for esophageal cancer using robot-assisted minimally invasive resections. Materials and methods. A retrospective analysis was conducted on 13 patients with intrathoracic esophageal cancer who underwent surgery between 2024 and 2025. All patients received Lewis and McKeown robot-assisted minimally invasive esophageal resections. The DaVinci Xi robotic platform was utilized during the thoracic stage in all cases. At the abdominal stage, both robotic and standard laparoscopic approaches were employed, with one patient requiring a laparotomy. Results. The mean duration of surgery was 424.2 ± 132.2 minutes (95% confidence interval: 344.2–504.1). Median intraoperative blood loss was 96.2 mL (interquartile range: 50–100). The median intensive care unit stay following surgery was 3 days (interquartile range: 1–2.5). Postoperatively, pneumonia was the most frequent complication, occurring in three patients (23%). The most severe complication was esophagogastric anastomosis dehiscence, observed in two patients (15%). In one case (7.7%), esophagogastric anastomosis dehiscence following Lewis surgery resulted in death. Conclusion. Robot-assisted resection for esophageal cancer represents an advanced and promising surgical approach that integrates oncological radicality with enhanced safety.
- 19 August 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (4)
Metastasis of thyroid cancer to retroperitoneal lymph nodes and breast
The article presents a clinical observation of a patient with papillary thyroid cancer and atypical metastatic lesion of retroperitoneal lymph nodes and left breast, who underwent complex treatment in the Moscow City Oncological Hospital No. 62 of the Department of Health of Moscow.
- 19 August 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (4)
Metastasis of thyroid cancer to retroperitoneal lymph nodes and breast
The article presents a clinical observation of a patient with papillary thyroid cancer and atypical metastatic lesion of retroperitoneal lymph nodes and left breast, who underwent complex treatment in the Moscow City Oncological Hospital No. 62 of the Department of Health of Moscow.
- Open Access
- 9 August 2024
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 15 (2) , 77-84
The possibilities of CT and MRI in design of treatment for colorectal liver metastases: a prospective study
INTRODUCTION: Frequent detection of liver metastases in colorectal cancer and a high risk of adverse outcomes determine the algorithm for managing such patients, involving maximum early diagnosis and selection of treatment methods.OBJECTIVE: To demonstrate the possibilities of CT and MRI in determining treatment tactics for colorectal liver metastases. MATERIALS AND METHODS: 90 patients with metastatic colorectal cancer in the liver were examined. All patients underwent contrast-enhanced CT. Multiparametric magnetic resonance imaging was performed in 49 patients (54%). The diagnosis was confirmed morphologically and/or by at least one additional method of examination (ultrasound or PET/CT).RESULTS: When a solitary metastatic lesion in the liver or a limited number of lesions within one segment or lobe was identified, the preferred method was typical or atypical liver resection together with drug therapy (38.9%). In the presence of several small metastatic lesions, each with a diameter not exceeding 3 cm, and located far apart from each other, radiofrequency ablation was an additional method to liver resection (4.4%). For unresectable patients and/or non-resectable solitary lesions smaller than 5 cm without evidence of vascular invasion, the preferred method was stereotactic body radiation therapy (SBRT) (13.3%). Marked reduction in liver functional reserve, small remaining liver volume, as well as bilobar involvement precluded the resection of all lesions. Therefore, in cases of bilobar liver involvement where organ-preserving surgery is not feasible, with the presence of extrahepatic metastases, and when the patient is functionally unresectable, the preferred method was drug therapy (33.4%), transarterial chemoembolization (TACE) as a palliative therapy (10%).DISCUSSION: According to the literature, the most sensitive methods for detecting liver metastases are MRI with diffusionweighted imaging (DWI) and the use of hepatospecific contrast agents in the hepatobiliary phase. CT is a reliable method for preoperative staging, providing high-quality visualization of the liver and covering the entire abdominal and thoracic cavities, allowing for the detection of metastases in regional lymph nodes and distant metastases. The statistical regularity we identified confirms these findings. However, in several studies, it has been noted that the sensitivity of MRI with hepatospecific contrast agents in the hepatobiliary phase is higher than DWI when detecting small lesions (less than 10 mm). According to the results of our study, MRI with DWI was found to be more sensitive for detecting small metastatic lesions.CONCLUSION: Contrast-enhanced CT and multiparametric MRI showed high diagnostic value in the assessment of metastatic colorectal cancer in the liver for planning radical surgical intervention and selecting alternative treatment methods.
- 9 August 2024
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 15 (2) , 77-84
Open AccessThe possibilities of CT and MRI in design of treatment for colorectal liver metastases: a prospective study
INTRODUCTION: Frequent detection of liver metastases in colorectal cancer and a high risk of adverse outcomes determine the algorithm for managing such patients, involving maximum early diagnosis and selection of treatment methods.OBJECTIVE: To demonstrate the possibilities of CT and MRI in determining treatment tactics for colorectal liver metastases. MATERIALS AND METHODS: 90 patients with metastatic colorectal cancer in the liver were examined. All patients underwent contrast-enhanced CT. Multiparametric magnetic resonance imaging was performed in 49 patients (54%). The diagnosis was confirmed morphologically and/or by at least one additional method of examination (ultrasound or PET/CT).RESULTS: When a solitary metastatic lesion in the liver or a limited number of lesions within one segment or lobe was identified, the preferred method was typical or atypical liver resection together with drug therapy (38.9%). In the presence of several small metastatic lesions, each with a diameter not exceeding 3 cm, and located far apart from each other, radiofrequency ablation was an additional method to liver resection (4.4%). For unresectable patients and/or non-resectable solitary lesions smaller than 5 cm without evidence of vascular invasion, the preferred method was stereotactic body radiation therapy (SBRT) (13.3%). Marked reduction in liver functional reserve, small remaining liver volume, as well as bilobar involvement precluded the resection of all lesions. Therefore, in cases of bilobar liver involvement where organ-preserving surgery is not feasible, with the presence of extrahepatic metastases, and when the patient is functionally unresectable, the preferred method was drug therapy (33.4%), transarterial chemoembolization (TACE) as a palliative therapy (10%).DISCUSSION: According to the literature, the most sensitive methods for detecting liver metastases are MRI with diffusionweighted imaging (DWI) and the use of hepatospecific contrast agents in the hepatobiliary phase. CT is a reliable method for preoperative staging, providing high-quality visualization of the liver and covering the entire abdominal and thoracic cavities, allowing for the detection of metastases in regional lymph nodes and distant metastases. The statistical regularity we identified confirms these findings. However, in several studies, it has been noted that the sensitivity of MRI with hepatospecific contrast agents in the hepatobiliary phase is higher than DWI when detecting small lesions (less than 10 mm). According to the results of our study, MRI with DWI was found to be more sensitive for detecting small metastatic lesions.CONCLUSION: Contrast-enhanced CT and multiparametric MRI showed high diagnostic value in the assessment of metastatic colorectal cancer in the liver for planning radical surgical intervention and selecting alternative treatment methods.
- Open Access
- 22 October 2023
- Published by Alfmed LLC in Medical alphabet
- No. 17,p. 17-21
Role of multidisciplinary team in management of unresectable HCC: Opportunities that exist today
Hepatocellular cancer (HCC) is one of the most common and, at the same time, little-known gastrointestinal oncopathologies in wide clinical practice. HCC ranks 5th in the world in the structure of oncological morbidity and 3rd in cancer mortality. HCC accounts for 70–85 % of all primary liver tumors. The involvement of doctors from various specialties is considered the most effective approach to cancer treatment in today’s dynamic and complex healthcare system. One of the nosologies where the introduction and application of a multidisciplinary consultation system is extremely important is HCC, because a large number of clinicians of various specialties are involved in the treatment of these patients. The effectiveness of an interdisciplinary approach in patients with HCC has been confirmed by clinical studies. However, the creation of such multidisciplinary consultations for patients with HCC has quite objective difficulties: A low percentage of curable patients at the time of detection of this disease and diagnosis, either due to the initially disseminated tumor process, or due to the initially low functional status of these patients. Overcoming these obstacles and creating such teams, their wide replication and integration into clinical practice will increase the number of patients detected at earlier stages and naturally improve the immediate and long-term results of treatment of such patients
- 22 October 2023
- Published by Alfmed LLC in Medical alphabet
- No. 17,p. 17-21
Open AccessRole of multidisciplinary team in management of unresectable HCC: Opportunities that exist today
Hepatocellular cancer (HCC) is one of the most common and, at the same time, little-known gastrointestinal oncopathologies in wide clinical practice. HCC ranks 5th in the world in the structure of oncological morbidity and 3rd in cancer mortality. HCC accounts for 70–85 % of all primary liver tumors. The involvement of doctors from various specialties is considered the most effective approach to cancer treatment in today’s dynamic and complex healthcare system. One of the nosologies where the introduction and application of a multidisciplinary consultation system is extremely important is HCC, because a large number of clinicians of various specialties are involved in the treatment of these patients. The effectiveness of an interdisciplinary approach in patients with HCC has been confirmed by clinical studies. However, the creation of such multidisciplinary consultations for patients with HCC has quite objective difficulties: A low percentage of curable patients at the time of detection of this disease and diagnosis, either due to the initially disseminated tumor process, or due to the initially low functional status of these patients. Overcoming these obstacles and creating such teams, their wide replication and integration into clinical practice will increase the number of patients detected at earlier stages and naturally improve the immediate and long-term results of treatment of such patients